Implantica accelerates its US market entry as prominent surgeons begin training on the RefluxStop device, aiming to treat millions of patients suffering from GERD without the side effects of traditional surgery.
Implantica has reached a critical operational milestone as leading US surgeon Dr. John C. Lipham begins training for the RefluxStop procedure, signaling the start of the company's US commercial rollout. With FDA approval already secured and additional US surgeons scheduled for training in November, the company is actively transitioning from a European-focused entity to a US-market participant. This progress addresses a massive addressable market of 78 million Americans suffering from acid reflux, providing a clear path for revenue growth.
RefluxStop restores the natural barrier against reflux without tightening the esophagus, thereby avoiding common side effects like swallowing difficulties, gas, and bloating.
Over 1,800 patients have been treated at more than 60 Centers of Excellence across nine European countries.
Implantica AG has initiated the training of top US surgeons, including Dr. John C. Lipham, for its FDA-approved RefluxStop device. This move marks a critical step in the company's US commercial rollout, targeting a market of 78 million Americans suffering from acid reflux. With FDA approval secured and training programs underway in Europe, the company is preparing to address significant unmet demand for its non-constrictive reflux treatment.
The training program is a prerequisite for the commercial launch of RefluxStop in the US, ensuring that top-tier surgeons are proficient in the procedure following the device's FDA approval.